1600565-34-1

Upstream product

• 231291-22-8 6-trifluoromethylnicotinic acid 
• 358780-13-9 6-(trifluoromethyl)nicotinoyl chloride 
• 416852-53-4 N-methoxy-N-methyl-6-(trifluoromethyl)pyridine-3-carboxamide 
• 909365-96-4 6-bromo-4-hydroxy-3-phenylquinolin-2(1H)-one 
• 452349-62-1 methyl 5-bromo-2-(2-phenylacetamido)benzoate 
• 103-80-0 phenylacetyl chloride 
• 52727-57-8 5-bromo-2-aminobenzoic acid methyl ester 
• 1600562-81-9 6-bromo-2,4-dichloro-3-phenylquinoline 
• 1600562-98-8 (3-chlorophenyl)(6-(trifluoromethyl)pyridin-3-yl)methanone 

Downstream Products

• 1600565-39-6 6-{(3-chlorophenyl)(hydroxy)[6-(trifluoromethyl)pyridin-3-yl]methyl}-3-phenylquinoline-2,4-dicarbonitrile 

Relevant academic research and scientific papers

PHENYL LINKED QUINOLINYL MODULATORS OF RORyt

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also

PHENYL LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T

The present invention comprises compounds of Formula I. Formula I wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The inve

HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt

The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating RORγt activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.